Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer.

摘要: A large number of monoclonal antibodies (MAbs) to various tumor cell lines have been developed (1). However, MAbs thus far had limited therapeutic impact in oncology, probably part because many murine do not effectively recruit immune effector mechanisms, such as complement fixation and antibody-dependent cell-mediated cytotoxicity (ADCC) humans. Additionally, although humanized are being developed, when used therapeutically their immunological effectiveness may be by high concentrations nonspecific immunoglobulin (Ig) patient serum. These Ig will compete with conventional for binding Type I Fc receptors (FcγRI) on cells, therefore limit ability an response. Recently, however, clinical efficacy a MAb directed against HER-2/neu patients advanced breast cancer has demonstrated (2-4). Preclinical data suggests that mechanistically this activity consequence modulation important biologic properties the receptor itself, opposed through immunologic mechanism destruction.